Last mentioned: Mar 25, 2026
End of Certainty Period
The 21-year structured resolution period is slated to conclude.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
$7.25B Settlement Announced
Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
Future Claims Deal
Bayer reaches a $7.25 billion agreement to resolve future litigation over a 21-year period.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Initial $10B Settlement
Bayer announces a massive settlement to resolve current claims, but future liability remains.
Initial Settlement
Bayer announces a $10.9 billion settlement to resolve the majority of existing Roundup claims.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
First Major Verdict
A California jury awards $289M to a groundskeeper, sparking a wave of litigation.
Monsanto Acquisition
Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
Monsanto Acquisition
Bayer completes the $63 billion acquisition of Monsanto, inheriting Roundup liabilities.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Bayer has reached a definitive $7.25 billion settlement to resolve future Roundup litigation, implementing a 21-year framework designed to provide financial and legal certainty. The deal aims to move the German conglomerate past the glyphosate-related liabilities that have weighed on its valuation since the 2018 Monsanto acquisition.
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.